The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
MedPage Today on MSN3d
FDA Expands Guselkumab Approval to Crohn's DiseaseThe FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...
June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Apr. 24, 2024 — Study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback